Bolus and infusional 5-fluorouracil combined with cisplatin in advanced gastric cancer

Oncology Reports

Volumn 7, Issue 6, 2000, Pages 1305-1309

  Barone, Carlo ^a   Cassano, Alessandra ^a   Landriscina, Matteo ^a   Longo, Raffaele ^a   Astone, Antonio ^a   Pozzo, Carmelo ^a  

^a CATHOLIC UNIVERSITY   (Italy)

Author keywords

5 fluorouracil; Advanced gastric cancer; Biomodulation; Cisplatin

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; FLUOROURACIL; FOLINIC ACID; METHOTREXATE;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; DRUG ADMINISTRATION; DRUG POTENTIATION; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; MIDDLE AGED; PATHOLOGY; PILOT STUDY; STOMACH TUMOR;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; DRUG ADMINISTRATION SCHEDULE; DRUG SYNERGISM; FEMALE; FLUOROURACIL; HUMANS; INFUSIONS, INTRAVENOUS; LEUCOVORIN; MALE; METHOTREXATE; MIDDLE AGED; PILOT PROJECTS; STOMACH NEOPLASMS;

EID: 0034323193     PISSN: 1021335X     EISSN: None     Source Type: Journal    
DOI: 10.3892/or.7.6.1305     Document Type: Article

References (33)

1. McDonald JS, Schein PS, Woolley PV, Smythe T, Ueno W and Hoth D: 5-FIuorouracil, mitomycin C and adriamycin (FAM): a new combination chemotherapy program for advanced gastric carcinoma. Ann Intern Med 93: 533-536, 1980.
2. Klein HO, Wickramanayake PD, Dieterlc F, Mohr R, Oerkermann H and Gross R: High methotrexate/5-fluorouracil and adriamycin for gastric cancer. Semin Oncol 10 (Suppl 2): 29-31, 1983.
3. Preusser P, Wilke H, Achterrath W, Fink U, Lenaz L, Hciniche A, Meyer J, Meyer HJ and Buente H: Phase II study with the combination etoposide, doxorubicin and cisplatin in advanced measurable gastric cancer. J Clin Oncol 7: 1310-1317, 1989.
4. Cocconi G, Bella M, Zironi S, Algeri S, Di Costanzo F, De Lisi V, Luppi G, Mazzocchi B, Rodino C and Soldani M: Fluorouracil, doxorubicin, and mitomycin combination versus PELF chemotherapy in advanced gastric cancer: a prospective randomized trial of the Italian oncology group for clinical research. J Clin Oncol 12: 2687-2693, 1994.
5. Rougier PH, Ducreux M, Mahjoubi M, Pignon JP, Bellefqih S, Oliveira J, Bognel C, Lasser PH, Ychou M, Elias D, Cvitkovic E, Armand JP and Droz JP: Efficacy of combined 5-fluorouracil and cisplatinum in advanced gastric carcinomas. A phase II trial with prognostic factor analysis. Eur J Cancer 9: 1263-1269, 1994.
6. Wilke H. Preusser P, Fink U, Achterrath W, Lenaz L, Stahl M, Schober C, Link H, Meyer HJ, Lucke B and Schmoll HJ: High dose folinic acid, etoposide and 5-fluorouracil in advanced gastric cancer: a phase II study in elderly patients or patients with cardiac risk. Inv New Drugs 8: 65-70, 1990.
7. Findlay M, Cunningham D, Norman A, Mansi J, Nicolson M, Hickish T, Nicolson V, Nash A, Sacks N, Ford H, Carter R and Hill A: A phase II study in advanced gastrocsophageal cancer using epirubicin and cisplatin in combination with continuous infusion 5-fluorouracil (ECF). Ann Oncol 5: 609-616, 1994.
8. Barone C, Cassano A, Astone A, Ricevuto E, Fontana T, Noviello MR, Garufi C, Pacelli F and Grieco A: Association of epirubicin, etoposide and cisplatin in gastric cancer. A phase II study. Oncology 48: 353-355, 1991.
9. Wils JA, Klein HO, Wagener DJT, Bleiberg H, Reis H, Korsten F, Conroy TH, Fickers M, Leyvraz S, Buyse M and Duez N for the European Organization for Research and Treatment of Cancer: Sequential high dose methotrexate and fluorouracil combined with doxorubicin - A step ahead in the treatment of advanced gastric cancer: a trial of the European Organization for Reserch and Treatment of Cancer Gastrointestinal Tract Cooperative Group. J Clin Oncol 9: 827-831, 1991.
10. Kelsen D, Atiq OT, Saltz L, Niedzwiecki D, Ginn D, Chapman D, Heelan R, Lightdale C, Vinciguerra V and Brennan M: FAMTX versus etoposide, doxorubicin and cisplatin: a random assignment trial in gastric cancer. J Clin Oncol 10: 541-548, 1992.
11. Rougier P, Wils J, Wilke H, Lacave A, Van Cutsem E, Vanhöfer U, Sahmoud T, Curran D and Marinus A: Advanced gastric cancer: comparison of FAMTX (5FU, adriamycin, methotrexate) versus ELF (etoposidc, 5FU, leucovorin) versus FUP (infusional FU + cisplatin). Results from an EORTC trial of the GITCCG and the Arbeitsgemeinschaft für Innere Onkologie (AIO). Eur J Cancer 31A (Suppl. 5): abs. 546, 1995.
12. Webb A, Cunnigham D, Scarffe JH, Harper P, Norman A, Joffe JK, Hughes M, Mansi J, Findlay M, Hill A, Oates J, Nicolson M, Hickish T, O'Brien M, Iveson T, Watson M, Underhill C, Wardley A and Meehan M: Randomized trial comparing epirubicin, cisplatin and fluorouracil versus fluorouracil, doxorubicin and methotrexate in advanced esophagogastric cancer. J Clin Oncol 15: 261-267, 1997.
13. Machover D, Goldschmidt E, Chollet P, Metzger G, Zittoun J, Marquet J, Vandenbulcke JM, Misset JL, Schwarzenberg L, Fourtillan JB, Gagel H and Mathé G: Treatment of advanced colorectal and gastric adenocarcinoma with 5-fluorouracil and high-dose folinic acid. J Clin Oncol 4: 685-696, 1986.
14. Arbuck SG, Douglass HO Jr, Trave F, Milliron S, Baroni M and Nava H: A phase II trial of 5-fluorouracil and high dose intravenous leucovorin in gastric carcinoma. J Clin Oncol 5: 1150-1156, 1987.
15. Barone C, Corsi DC, Pozzo C, Cassano A, Fontana T, Noviello MR, Landriscina M, Colloca G and Astone A: Treatment of advanced gastric cancer with a 5-fluorouracil- or a cisplatin-based regimen: two parallel randomized phase II studies. Cancer 82: 1460-1467, 1998.
16. Sobrero AF, Aschele C and Bertino JR: Fluorouracil in colorectal cancer: a tale of two drugs: implications for biochemical modulation. J Clin Oncol 15: 368-381, 1997.
17. Advanced Colorectal Cancer Meta-Analysis Project: Meta-analysis of randomized trials testing the biochemical modulation of fluorouracil by methotrexate in metastatic colon cancer. J Clin Oncol 12: 960-969, 1994.
18. Meta-analysis Group in Cancer: Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. J Clin Oncol 16: 301-308, 1998.
19. Moynihan T, Hansen R and Anderson T: Continuous 5-FU infusion in advanced gastric carcinoma. Am J Clin Oncol 11: 461-464, 1988.
20. Wils J: The treatment of advanced gastric cancer. Semin Oncol 23: 397-406, 1996.
21. Chen JS, Liu HE, Wang CH, Yang TS, Wang HM, Liau CT, Chang WC and Lin YC: Weekly 24-h infusion of high-dose 5-fluorouracil and leucovorin in patients with advanced gastric cancer. Anticanccr Drugs 101: 355-359, 1999.
22. Shirasaka T, Shimamoto Y Ohshimo H, Saito H and Fukushima M: Metabolic bases of synergistic antitumor activities of 5-fluorouracil and cisplatin in rodent tumor models in vivo. Cancer Chemother Pharmacol 32: 167-172, 1993.
23. Hryniuk WM: Average relative dose intensity and the impact on design of clinical trial. Semin Oncol 14: 65-74, 1987.
24. Kintzel PE and Dorr RT: Anticancer drug renal toxicity and elimination: dosing guidelines for altered renal function. Cancer Treat Rev 21: 33-64, 1995.
25. Fishman B, Pasternak S, Wallenstein SL, Houde RW, Holland JC and Foley KM: The Memorial Pain Assessment Card: a valid instrument for the evaluation of cancer pain. Cancer 60: 1151-1158, 1987.
26. Kaplan EL and Meier P: Non-parametric estimation from incomplete observation. J Am Stat Assoc 53: 457-481, 1958.
27. Bruckner HW, Chesser MR, Wong H and Mandeli J: Folate biochemical modulation regimen for the treatment of gastric concer. J Clin Gastroenterol 13: 384-389, 1991.
28. Leichman L and Berry BT: Cisplatin therapy for adenocarcinoma of the stomach. Semin Oncol 18: 25-33, 1991.
29. De Gramont A, Bosset JF, Milan C, Rougier P, Bouché O, Etienne PL, Morvan F, Louvet C, Guillot T, Francois E and Bedenne L: Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study. J Clin Oncol 15: 808-815, 1997.
30. Kim NK, Park YS, Heo DS, Suh C, Kim SY, Park KC, Kang-YK, Shin DB, Kim HT, Kim HJ, Kang WK, Suh CI and Bang YJ: A phase III randomized study of 5-fluorouracil and cisplatin versus 5-fluorouracil, doxorubicin and mytomycin C versus 5-fluorouracil alone in the treatment of advanced gastric cancer. Cancer 71: 3813-3818, 1993.
31. Zaniboni A. Bami S, Labianca R, Marini G, Pancera G, Giaccon G, Piazza E, Signaroldi A, Legnani W and Luporini G for the Italian Group for the Study of Digestive Tract Cancer (GISCAD): Epirubicin, cisplatin and continuous infusion 5-fluorouracil is an active and safe regimen for patients with advanced gastric cancer. Cancer 76: 1694-1699, 1995.
32. Lokich J and Anderson N: Dose intensity for bolus versus infusion chemotherapy administration: review of the literature for 27 antineoplastic agents. Ann Oncol 1: 15-25, 1997.
33. Colucci G, Giotta F, Maiello E, Cifarclli RA, Leo S, Giuliani F, Pezzella G, Pedicini A and Valori V: Efficacy of the association of folinic acid and 5-fluorouracil plus 4-epidoxorubicin in the treatment of advanced gastric carcinoma. Am J Clin Oncol 18: 519-524, 1995.